Cardiac biomarkers 111813
•
1 like•1,045 views
There are about 50 million cardiac biomarker tests performed in the US annually, representing a $300 million to $1.25 billion market. If better biomarkers were developed, an additional 48.5 million tests could be performed for diagnosing and monitoring heart failure, representing a potential additional market of $40 million to over $1 billion. The document lists several companies that operate in the novel cardiac biomarker space and describes different types of biomarkers related to myocardial injury, stress, inflammation, and other cardiac and extra-cardiac factors that could help diagnose and manage conditions like acute coronary syndrome, heart failure, and stroke.
Recommended
More Related Content
What's hot
What's hot (19)
Similar to Cardiac biomarkers 111813
Similar to Cardiac biomarkers 111813 (20)
More from Winton Gibbons
More from Winton Gibbons (16)
Recently uploaded
Recently uploaded (20)
Cardiac biomarkers 111813
- 1. Novel Biomarker Firms Specialty Heart Labs Mainstream Alere Atherotech Mainframe diagnostics BG Medicine Aviir BRAHMS Berkeley Heart Laboratory Critical Diagnostics Boston Heart Diagnostics diaDexus POC diagnostics CardioDx • In the US, there are about 50 million troponin, BNP, and other cardiac assays performed annually. At a price of $6 to 25 per test, this equates to a current market of $300 million to $1.25 billion. Hazard Ratio of 3 or Greater Required by MDs to Use a Particular Assay Estimated Required Hazard Ratio Range • Moreover, if better biomarkers were available, market research suggests that an additional 6 ½ million acute and 42 million chronic tests could be done for heart failure discharge and monitoring for decompensation and hospital readmission. The resulting potential market would be $40 million to over $1 billion. FFA Sciences Cleveland Heart Laboratory LipoSciences Health Diagnostic Laboratory (HDL) MedTest | Point Scientific Singulex Nexus Diagnostics Extra-cellular matrix remodeling Myocyte injury and apoptosis Ischemic Cluster Reference laboratories Oxidative stress Autoantibodies Apo E genotype MPO AntioxLDL Antitroponin Extra-cardiac involvement Myocyte stress Neurohormones Cystatin C (NTpro)BNP Copeptin Adiponectin NGAL MRproANP ET-1 GlycoMark ® RDW GDF-15 MRproADM UCN-1 LpPLa2 Genotyping Deep vein thrombosis IL-6 ST2 Peripheral arterial disease CRP Troponin 9p21 Genotype CYP2C19 Genotype Pulmonary embolism Ischemic stroke Death rate / 100,000 KIF6 Genotype LPA-Intron 25 Genotype Multi-markers LPA-Aspirin Genotype Heart disease PTX3 Gene expression Stroke 179 Cancer TNF-a CHD Risks Smoker 173 25% Corus® CAD VAP® Test HDL Map™ Lipids (cholesterol) Heart Failure 25% readmission and 11% death 30-day rates (22% death at 1 year) Inflammation SLCO1B1 genotype 4q25-AF Risk Genotype Discharge of heart Failure Needs an Objective Measurement, and MDs seem Willing to Move to a Sufficiently Better Biomarker Other oxLDL Galectin-3 Acute coronary syndrome Cholesterol Balance™ NMR LipoProfile uFFA 39 Lower respiratory 42 Injuries High LDL 38 Diabetes High blood pressure 21 MIRISK® Other Source: AHA, ACC, NCHS, Van Kimmenade Clin Chem, market research 255 © 2013 Winton Gibbons 23% 12% Some risk factor, 47% No risk factor, 53%